Skip to main content

Table 4 gyrA and gyrB mutations in garenoxacin and sitafloxacin resistance

From: Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics

gyrA mutation data

gyrB mutation data

Mutation

Frequency

MIC levofloxacin

MIC garenoxacin

MIC sitafloxacin

Mutation

Frequency

MIC levofloxacin

MIC garenoxacin

MIC sitafloxacin

Bangladesh

Bangladesh

 N87K

9/29

4–16

1–2

0.063–0.5

 D481E

1/29

2

2

0.25

 D91N

8/29

2–64

1–8

0.063–0.25

 R484K

1/29

64

8

4

 D91G

5/29

2–4

1–2

0.063–0.25

 D481E, R484K

14/29

2–64

1–8

0.063–0.5

 D91Y

1/29

4

2

0.125

 No mutation

13/29

4–16

1–2

0.063–0.5

 N87K, D91N

1/29

64

64

2

 

 No mutation

5/29

4–16

1–2

0.063–0.25

Nepal

Nepal

 N87K

3/11

32

1–2

0.5

 E483K

1/10

32

4

0.5

 N87I

1/11

32

4

0.5

 No mutation

9/10

32

1–4

1–2

 D91N

2/11

32

2

0.125–1

 

 D91Y

1/11

32

2

0.25

 N87K, D91N

1/11

32

4

2

 D91N, R130K

1/11

32

2

1

 D91N, S63P

1/11

0.125

2

0.5

 No mutation

1/11

32

1

0.5

  1. MIC Minimum inhibitory concentration, μg/mL
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us